Figures & data
Table 1 Detectable mean change in outcome measures for sample size of n=20 at 0.05 significance level with 0.80 power
Figure 1 Flowchart of the screening, enrollment, and follow-up of participants in the study.
Source: Copyright ©2014. Dove Medical Press. Reproduced from Bisht B, Darling WG, Shivapour ET, et al. Multimodal intervention improves fatigue and quality of life of subjects with progressive multiple sclerosis: a pilot study. Degenerat Neurol Neuromuscul Dis. 2015;2015(5):19–35.Citation20
![Figure 1 Flowchart of the screening, enrollment, and follow-up of participants in the study.Source: Copyright ©2014. Dove Medical Press. Reproduced from Bisht B, Darling WG, Shivapour ET, et al. Multimodal intervention improves fatigue and quality of life of subjects with progressive multiple sclerosis: a pilot study. Degenerat Neurol Neuromuscul Dis. 2015;2015(5):19–35.Citation20](/cms/asset/788b699f-daea-43c3-9232-bf1dc7de1887/dnnd_a_128872_f0001_b.jpg)
Figure 2 Time to complete timed up and go test at baseline, 3, 6, 9, and 12 months of the entire cohort (n=20), responders (n=10) and nonresponders (n=10).
![Figure 2 Time to complete timed up and go test at baseline, 3, 6, 9, and 12 months of the entire cohort (n=20), responders (n=10) and nonresponders (n=10).](/cms/asset/2cf0212f-7edc-4e4c-b914-839b86e38305/dnnd_a_128872_f0002_b.jpg)
Figure 3 Walking speed during 25-foot walk test at baseline, 3, 6, 9, and 12 months of the entire cohort (n=20), responders (n=10) and nonresponders (n=10).
Abbreviation: TUG, timed up and go.
![Figure 3 Walking speed during 25-foot walk test at baseline, 3, 6, 9, and 12 months of the entire cohort (n=20), responders (n=10) and nonresponders (n=10).](/cms/asset/0d8eea1d-44bf-4ace-86f5-d153ca040672/dnnd_a_128872_f0003_b.jpg)
Figure 4 Speed to walk toward 10 feet mark during timed up and go test at baseline, 3, 6, 9, and 12 months of the entire cohort (n=20), responders (n=10) and nonresponders (n=10).
![Figure 4 Speed to walk toward 10 feet mark during timed up and go test at baseline, 3, 6, 9, and 12 months of the entire cohort (n=20), responders (n=10) and nonresponders (n=10).](/cms/asset/ae648b58-2b31-4466-8308-895cf176f79b/dnnd_a_128872_f0004_b.jpg)
Table 2 Mean change (95% CI) at 6, 9, and 12 months (all subjects)
Figure 5 Berg Balance Scale scores of the entire cohort (n=20), and responders (n=10) and nonresponders (n=10) to TUG test at baseline (B), 3, 6, 9, and 12 months.
Abbreviation: TUG, timed up and go.
![Figure 5 Berg Balance Scale scores of the entire cohort (n=20), and responders (n=10) and nonresponders (n=10) to TUG test at baseline (B), 3, 6, 9, and 12 months.](/cms/asset/d0a4f113-e74b-4ca1-96a7-c8bd3b5d8749/dnnd_a_128872_f0005_b.jpg)
Table 3 Mean change (95% CI) at 6, 9, and 12 months for responder and nonresponder
Figure 6 Spatio temporal gait parameters during timed up and go test at baseline, 3, 6, 9, and 12 months of responders (n=10) and nonresponders (n=10).
![Figure 6 Spatio temporal gait parameters during timed up and go test at baseline, 3, 6, 9, and 12 months of responders (n=10) and nonresponders (n=10).](/cms/asset/58dd3ae5-dd30-4d5d-9e58-daa4c07239d5/dnnd_a_128872_f0006_b.jpg)
Table 4 Baseline variables – responder vs nonresponder
Figure 7 Correlation between changes in fatigue severity scale scores over 3 months and change in 25-foot walk speed over 12 months.
Abbreviations: CI, confidence interval.
![Figure 7 Correlation between changes in fatigue severity scale scores over 3 months and change in 25-foot walk speed over 12 months.](/cms/asset/6e5c0af6-57eb-4ffb-85f0-2043ea31b58b/dnnd_a_128872_f0007_b.jpg)